MOTS-c Benefits: The Claims, Against the Numbers

The table becomes easier to use once the rows are grouped by what kind of statement they are.

The first bucket is mechanism. A pathway described in cultured cells is a claim about how something could work. It is genuine laboratory output and it is not an outcome. A mechanism can be real and still lead nowhere useful, because the step from a signal in a dish to a change worth noticing in a person is where most candidate compounds stop.

The second bucket is animal outcome. Work in mice reports a measured change under a defined protocol, in a defined strain, on a controlled diet. That is a result. It is a result about mice, and the amounts that produced it are stated per kilogram of mouse.

The third bucket is human outcome, and for this compound it is empty. Not disputed, not contested, empty. Nothing has been published that measured a change in people against a control group.

Vendor copy mixes the three freely, borrowing the confidence of the first two buckets for a claim that belongs in the third. Reading any benefits list with those three labels in hand does most of the sorting work automatically.

Search the registry and a record appears that seems to fill the third bucket. NCT07505745 is listed as a Phase 2 study of MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight or obesity, enrolment 120, status recruiting. It has the shape of an answer, which is precisely the problem.

It does not survive being opened. Its lead sponsor, Hudson Biotech, holds eight registry entries posted between February and April 2026, one each for BPC-157, Melanotan II, GHK-Cu, retatrutide, tesamorelin, tirzepatide, TB-500 and MOTS-c, all recruiting, all at a single site. That is a vendor catalogue with NCT numbers attached, not a research programme. NCT07487363, the TB-500 entry, states in its own brief summary that it is a fictional example of a ClinicalTrials.gov-style record, and no Hudson Biotech application appears in the FDA approved drug database.

The other records that search returns are false matches of the ordinary kind, thrown up because it looks for the text anywhere in a study description rather than in the intervention field. So the third bucket stays empty, and it is worth being exact about why it stays empty. A registration is a submission the registry accepted, not a study anyone ran. An NCT number in a benefits list is a citation in the typographic sense only.

There is no marketing authorisation from the FDA, the EMA or the MHRA. The compound is sold as a research chemical, and that status carries directly into the arithmetic below.

A benefit claim attaches to an amount, and an amount only exists once a vial has been prepared. The vial arrives as a dry powder with a labelled mass. Until liquid is added, no volume corresponds to any mass at all.

Concentration is the labelled mass divided by the volume of bacteriostatic water added. A 10 mg vial with 2 mL gives 10 divided by 2, which is 5 mg per mL. The mass in a given draw is that concentration multiplied by the volume drawn. A U-100 insulin syringe holds 1 mL at 100 units, so one unit is 0.01 mL, and 10 units are 0.1 mL. At 5 mg per mL, that draw holds 5 times 0.1, which is 0.5 mg, or 500 mcg.

Change one input and everything downstream changes. The same 10 mg vial with 5 mL gives 2 mg per mL, and the same 10 units then hold 200 mcg. The powder was identical. The label was identical. The amount in the syringe differs by a factor of two and a half.

This is why a claim of the form "I used 250 mcg" is only half written. The other half is the preparation that made 250 mcg readable on a barrel, and it is the half that vendor copy and forum posts leave out.

Animal work reports amounts per kilogram of body weight, alongside a route, a schedule and a strain. That is a complete specification for a mouse experiment. The temptation is to multiply the figure by a person's body mass and call the result a human amount.

The multiplication is trivial. It is also meaningless. Clearance rates differ between species, the route used in an animal model may not be the route a person would use, and the models themselves, an inbred strain on a controlled diet in a controlled light cycle, are chosen because they isolate a variable rather than because they resemble a person. Nothing in the arithmetic flags this. It will produce a tidy number from any inputs it is given, which is precisely why the tidy number is dangerous.

This page therefore gives no human figure at all. Not a conservative one, not a range, not a starting point. The arithmetic here converts between mass, volume and syringe graduations, and it stops at the edge of the vial.

One comparison does survive across vials of different sizes:

cost per mg = price paid / labelled mass

Using assumed figures, since prices move and no seller is named here: a 5 mg vial at 55 currency units is 55 divided by 5, or 11 per mg. A 10 mg vial at 90 is 90 divided by 10, or 9 per mg. The larger vial costs more at checkout and less per mg, which is the arithmetic a headline price hides.

The formula divides by the labelled mass, and the label is a claim rather than a measurement. A seller who overstates the label wins on this metric without shipping anything extra. Cost per mg ranks sellers only inside a group whose labels have been independently assayed. Across an assayed vial and an unassayed one it compares nothing, and no amount of decimal places changes that.

The maths on this page is exact and narrow. Given an accurate label and a recorded fill volume, it tells you the mass in any volume you draw, and it tells you what a vial costs per mg. It inherits the label's error when the label is wrong, and it is silent on purity, on stability after reconstitution, and on whether any of the claims in the opening table hold in a person.

Those are questions for assay and for trials, not for division. Three of them can be answered today by a laboratory. The fourth is waiting on a study nobody has run.